{
  "body": "<h2>Pre-Payment Review Results for Remicade&reg; (Infliximab) for Targeted Probe and Educate (TPE) for October to December 2024</h2>\n\n<p style=\\\"margin-bottom:10pt; margin-left:0in; margin-right:0in; margin-top:0in\\\">The Centers for Medicare &amp; Medicaid Services (CMS) implemented the TPE&nbsp;process for Healthcare Common Procedure Coding System (HCPCS) code J0178 for Remicade&reg; (Infliximab). The reviews with edit effectiveness are presented here for North Carolina, South Carolina, Virginia&nbsp;and West Virginia.</p>\n\n<h3 style=\\\"margin-left:0in; margin-right:0in\\\">Cumulative Results</h3>\n\n<table border=\\\"1\\\" cellspacing=\\\"0\\\" class=\\\"MsoTableGrid\\\" style=\\\"border-collapse:collapse; border:solid windowtext 1.0pt\\\">\n\t<caption>Table 1. Cumulative Results.</caption>\n\t<thead>\n\t\t<tr>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:116.85pt\\\">Number of Providers with Edit Effectiveness</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:116.85pt\\\">Providers Compliant Completed/Removed After Probe</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:116.9pt\\\">Providers Non-Compliant Progressing to Subsequent Probe</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:116.9pt\\\">Providers Non-Compliant/Removed for Other Reason</th>\n\t\t</tr>\n\t</thead>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\\\"height:1px; text-align:center; vertical-align:middle; width:116.85pt\\\">4</td>\n\t\t\t<td style=\\\"height:1px; text-align:center; vertical-align:middle; width:116.85pt\\\">4</td>\n\t\t\t<td style=\\\"height:1px; text-align:center; vertical-align:middle; width:116.9pt\\\">0</td>\n\t\t\t<td style=\\\"height:1px; text-align:center; vertical-align:middle; width:116.9pt\\\">0</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<table border=\\\"1\\\" cellspacing=\\\"0\\\" class=\\\"MsoTableGrid\\\" style=\\\"border-collapse:collapse; border:solid windowtext 1.0pt; width:100.0%\\\">\n\t<caption>Table 2. Cumulative Results.</caption>\n\t<thead>\n\t\t<tr>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:20.22%\\\">Number of Claims with Edit Effectiveness</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:14.9%\\\">Number of Claims Denied</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:13.86%\\\">Overall Claim Denial Rate</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:15.56%\\\">Total Dollars Reviewed</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:20.66%\\\">Total Dollars Denied</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:14.8%\\\">Overall Charge Denial Rate</th>\n\t\t</tr>\n\t</thead>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:20.22%\\\">84</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:14.9%\\\">9</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:13.86%\\\">11%</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:15.56%\\\">$105,353.27</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:20.66%\\\">$7,782.38</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:14.8%\\\">7%</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<h3 style=\\\"margin-left:0in; margin-right:0in\\\">Probe One Findings</h3>\n\n<table border=\\\"1\\\" cellspacing=\\\"0\\\" class=\\\"MsoTableGrid\\\" style=\\\"border-collapse:collapse; border:solid windowtext 1.0pt\\\">\n\t<caption>Table 3. Probe One Findings.</caption>\n\t<thead>\n\t\t<tr>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:69.45pt\\\">State</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:93.45pt\\\">Number of Providers with Edit Effectiveness</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:107.4pt\\\">Providers Compliant Completed/Removed After Probe</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:90.5pt\\\">Providers Non-Compliant Progressing to Subsequent Probe</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:106.7pt\\\">Providers Non-Compliant/Removed for Other Reason</th>\n\t\t</tr>\n\t</thead>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\\\"height:14.35pt; text-align:center; vertical-align:middle; width:69.45pt\\\">N.C.</td>\n\t\t\t<td style=\\\"height:14.35pt; text-align:center; vertical-align:middle; width:93.45pt\\\">3</td>\n\t\t\t<td style=\\\"height:14.35pt; text-align:center; vertical-align:middle; width:107.4pt\\\">3</td>\n\t\t\t<td style=\\\"height:14.35pt; text-align:center; vertical-align:middle; width:90.5pt\\\">0</td>\n\t\t\t<td style=\\\"height:14.35pt; text-align:center; vertical-align:middle; width:106.7pt\\\">0</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\\\"height:8.95pt; text-align:center; vertical-align:middle; width:69.45pt\\\">S.C.</td>\n\t\t\t<td style=\\\"height:8.95pt; text-align:center; vertical-align:middle; width:93.45pt\\\">1</td>\n\t\t\t<td style=\\\"height:8.95pt; text-align:center; vertical-align:middle; width:107.4pt\\\">1</td>\n\t\t\t<td style=\\\"height:8.95pt; text-align:center; vertical-align:middle; width:90.5pt\\\">0</td>\n\t\t\t<td style=\\\"height:8.95pt; text-align:center; vertical-align:middle; width:106.7pt\\\">0</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\\\"height:3pt; text-align:center; vertical-align:middle; width:69.45pt\\\">Va.</td>\n\t\t\t<td style=\\\"height:3pt; text-align:center; vertical-align:middle; width:93.45pt\\\">0</td>\n\t\t\t<td style=\\\"height:3pt; text-align:center; vertical-align:middle; width:107.4pt\\\">0</td>\n\t\t\t<td style=\\\"height:3pt; text-align:center; vertical-align:middle; width:90.5pt\\\">0</td>\n\t\t\t<td style=\\\"height:3pt; text-align:center; vertical-align:middle; width:106.7pt\\\">0</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\\\"height:3pt; text-align:center; vertical-align:middle; width:69.45pt\\\">W.Va.</td>\n\t\t\t<td style=\\\"height:3pt; text-align:center; vertical-align:middle; width:93.45pt\\\">0</td>\n\t\t\t<td style=\\\"height:3pt; text-align:center; vertical-align:middle; width:107.4pt\\\">0</td>\n\t\t\t<td style=\\\"height:3pt; text-align:center; vertical-align:middle; width:90.5pt\\\">0</td>\n\t\t\t<td style=\\\"height:3pt; text-align:center; vertical-align:middle; width:106.7pt\\\">0</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<table border=\\\"1\\\" cellspacing=\\\"0\\\" class=\\\"MsoTableGrid\\\" style=\\\"border-collapse:collapse; border:solid windowtext 1.0pt; width:100%\\\">\n\t<caption>Table 4. Probe One Findings.</caption>\n\t<thead>\n\t\t<tr>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:14.1%\\\">State</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:18.54%\\\">Number of Claims with Edit Effectiveness</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:12.52%\\\">Number of Claims Denied</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:12.5%\\\">Overall Claim Denial Rate</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:15.4%\\\">Total Dollars Reviewed</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:14.44%\\\">Total Dollars Denied</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:12.48%\\\">Overall Charge Denial Rate</th>\n\t\t</tr>\n\t</thead>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:14.1%\\\">N.C.</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:18.54%\\\">73</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:12.52%\\\">8</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:12.5%\\\">11%</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:15.4%\\\">$104,956.78</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:14.44%\\\">$7,744.70</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:12.48%\\\">7%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:14.1%\\\">S.C.</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:18.54%\\\">11</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:12.52%\\\">1</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:12.5%\\\">9%</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:15.4%\\\">$396.49</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:14.44%\\\">$37.68</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:12.48%\\\">10%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:14.1%\\\">Va.</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:18.54%\\\">0</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:12.52%\\\">0</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:12.5%\\\">0%</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:15.4%\\\">$0.00</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:14.44%\\\">$0.00</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:12.48%\\\">0%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:14.1%\\\">W.Va.</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:18.54%\\\">0</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:12.52%\\\">0</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:12.5%\\\">0%</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:15.4%\\\">$0.00</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:14.44%\\\">$0.00</td>\n\t\t\t<td style=\\\"text-align:center; vertical-align:middle; width:12.48%\\\">0%</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<h3 style=\\\"margin-left:0in; margin-right:0in\\\">Risk Category</h3>\n\n<p style=\\\"margin-bottom:10pt; margin-left:0in; margin-right:0in; margin-top:0in\\\">The categories for HCPCS&nbsp;code J0178 for Remicade&reg; (Infliximab) are defined as:</p>\n\n<table border=\\\"1\\\" class=\\\"Table\\\">\n\t<caption>Table 5. Risk Category.</caption>\n\t<thead>\n\t\t<tr>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:56%\\\">Risk Category</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"height:1px; text-align:center; vertical-align:middle; width:43.54%\\\">Error Rate</th>\n\t\t</tr>\n\t</thead>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\\\"background-color:white; height:0.9pt; text-align:center; vertical-align:middle; width:56%\\\">Minor</td>\n\t\t\t<td style=\\\"background-color:white; height:0.9pt; text-align:center; vertical-align:middle; width:43.54%\\\">0&ndash;20%</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\\\"background-color:white; height:0.9pt; text-align:center; vertical-align:middle; width:56%\\\">Major</td>\n\t\t\t<td style=\\\"background-color:white; height:0.9pt; text-align:center; vertical-align:middle; width:43.54%\\\">21&ndash;100%</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p>Figure 1. Risk Category for Remicade.</p>\n\n<p style=\\\"margin-bottom:10pt; margin-left:0in; margin-right:0in; margin-top:0in\\\"><img alt=\\\"Pie chart showing 100% minor findings\\\" src=\\\"https://www.palmettogba.com/palmetto/providers.nsf/Files/Risk_Category_Remicade.png/$FILE/Risk_Category_Remicade.png\\\" style=\\\"height:476px; width:700px\\\" /></p>\n\n<h3 style=\\\"margin-left:0in; margin-right:0in\\\">Top Denial Reasons</h3>\n\n<table border=\\\"1\\\" cellspacing=\\\"0\\\" class=\\\"Table\\\" style=\\\"border-collapse:collapse; border:1pt solid windowtext; margin-left:4.25pt\\\">\n\t<caption>Table 6. Top Denial Reasons.</caption>\n\t<thead>\n\t\t<tr>\n\t\t\t<th scope=\\\"col\\\" style=\\\"text-align:center; vertical-align:middle; width:71.45pt\\\">Percent of Total Denials</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"text-align:center; vertical-align:middle; width:96.15pt\\\">Denial Code</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"text-align:center; vertical-align:middle; width:400px\\\">Denial Description</th>\n\t\t\t<th scope=\\\"col\\\" style=\\\"text-align:center; vertical-align:middle; width:15px\\\">Number of Occurrences</th>\n\t\t</tr>\n\t</thead>\n\t<tbody>\n\t\t<tr>\n\t\t\t<td style=\\\"height:1px; text-align:center; vertical-align:middle; width:71.45pt\\\">50%</td>\n\t\t\t<td style=\\\"height:1px; text-align:center; vertical-align:middle; width:96.15pt\\\">NOTML</td>\n\t\t\t<td style=\\\"height:1px; text-align:center; vertical-align:middle; width:400px\\\">Per Applicable LCD, Payer Deems the Information Submitted Does Not Support the Medical Necessity of the Services Billed</td>\n\t\t\t<td style=\\\"height:1px; text-align:center; vertical-align:middle; width:15px\\\">2</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\\\"height:1px; text-align:center; vertical-align:middle; width:71.45pt\\\">25%</td>\n\t\t\t<td style=\\\"height:1px; text-align:center; vertical-align:middle; width:96.15pt\\\">NODOC</td>\n\t\t\t<td style=\\\"height:1px; text-align:center; vertical-align:middle; width:400px\\\">Documentation Requested for This Date of Service Was Not Received or Was Incomplete; Therefore We Are Unable to Make a Reasonable and Necessary Determination as Defined Under Section 1862(a) (1) (A) of the ACT for the Service Billed and This Service Has Been Denied</td>\n\t\t\t<td style=\\\"height:1px; text-align:center; vertical-align:middle; width:15px\\\">1</td>\n\t\t</tr>\n\t\t<tr>\n\t\t\t<td style=\\\"height:1px; text-align:center; vertical-align:middle; width:71.45pt\\\">25%</td>\n\t\t\t<td style=\\\"height:1px; text-align:center; vertical-align:middle; width:96.15pt\\\">BILER</td>\n\t\t\t<td style=\\\"height:1px; text-align:center; vertical-align:middle; width:400px\\\">Claim Billed in Error per Provider</td>\n\t\t\t<td style=\\\"height:1px; text-align:center; vertical-align:middle; width:15px\\\">1</td>\n\t\t</tr>\n\t</tbody>\n</table>\n\n<p style=\\\"margin-bottom:10pt; margin-left:0in; margin-right:0in; margin-top:0in\\\"><strong>NOTML &mdash;</strong>&nbsp;<strong>Per Applicable LCD, Payer Deems the Information Submitted Does Not Support the Medical Necessity of the Services Billed</strong></p>\n\n<ul>\n\t<li>Ensure that all documentation to support medical necessity of the service billed is submitted for review. This includes original chart notes and any diagnostic, radiological, or laboratory results.</li>\n\t<li>Verify that documentation to support the level of service billed is included<br />\n\t&nbsp;</li>\n</ul>\n\n<p style=\\\"margin-bottom:10pt; margin-left:0in; margin-right:0in; margin-top:0in\\\">NODOC &mdash;&nbsp;<strong>Documentation Requested for This Date of Service Was Not Received or Was Incomplete; Therefore We Are Unable to Make a Reasonable and Necessary Determination as Defined Under Section 1862(a) (1) (A) of the ACT for the Service Billed and This Service Has Been Denied</strong></p>\n\n<ul>\n\t<li>Submit all documentation related to the services billed within 45 days of the date on the ADR letter</li>\n\t<li>Review documentation prior to submission to ensure that the documentation is complete and that all dates of service requested are included</li>\n\t<li>Include any additional information pertinent to the date of service requested to support the services billed. For example: original chart notes, diagnostic, radiological or laboratory results.</li>\n\t<li>For claims denied with a M127 or N29 code listed on the remittance advice, be sure to submit all documentation for all dates of service on that claim with a reopen/redetermination request form by fax to JM Part&nbsp;B (803) 699&ndash;2427, JJ Part&nbsp;B (803) 870&ndash;0139, or RRB Appeals (803) 462&ndash;2218<br />\n\t&nbsp;</li>\n</ul>\n\n<p style=\\\"margin-bottom:10pt; margin-left:0in; margin-right:0in; margin-top:0in\\\"><strong>BILER &mdash; Claim Billed in Error per Provider</strong></p>\n\n<ul>\n\t<li>Prior to billing claims, review the information to determine that the correct information is listed in the appropriate fields</li>\n\t<li>For all claims previously billed and denied by medical review, do not resubmit the claims. If you disagree with the decision from Medical Review, you must submit the appropriate documentation with a completed redetermination request form to the appeals department. This information can be sent by fax to JM Part&nbsp;B Appeals&nbsp;(803) 699&ndash;2427, JJ Part&nbsp;B Appeals&nbsp;(803) 870&ndash;0139, or RRB Appeals (803) 462&ndash;2218.</li>\n\t<li>If documentation indicates that both an NPP and a physician performed the service, and the claim is billed under the physician&rsquo;s NPI, the billing physician <strong>must</strong> sign the record. Additionally, the documentation must include a statement that the billing provider had face-to-face contact with the patient and performed a substantive portion of the E/M visit. (A substantive portion of the E/M visit includes at least one of the three key components: history, exam, or medical decision-making.)</li>\n\t<li>If documentation occurs in a teaching environment, review the documentation to ensure that the billing provider has provided a teaching attestation and a signature<br />\n\t&nbsp;</li>\n</ul>\n\n<p class=\\\"MsoSubtitle\\\" style=\\\"margin-bottom:8pt; margin-left:0in; margin-right:0in; margin-top:0in\\\"><strong>Education</strong><br />\nPalmetto GBA offers providers selected for TPE an individualized education session to discuss each claim denial. This is an opportunity to learn how to identify and correct claim errors. A variety of education methods are offered such as webinar sessions, web-based presentations&nbsp;or teleconferences. Other education methods may also be available. Providers do not have to be selected for TPE to request education. If education is desired, please complete the <a href=\\\"https://palmettogba.com/palmetto/Mforms.nsf/files/PO-ALL-5000.pdf/$File/PO-ALL-5000.pdf?Open&amp;\\\" target=\\\"_blank\\\">Education Request Form</a>&nbsp;(PDF).&nbsp;</p>\n\n<p style=\\\"margin-bottom:10pt; margin-left:0in; margin-right:0in; margin-top:0in\\\"><strong>Next Steps</strong><br />\nProviders found to be non-compliant (major risk category/denial rate of 21&ndash;100 percent) at the completion of TPE Probe 1 will advance to Probe 2, and providers found to be non-compliant (major risk category/denial rate of 21&ndash;100 percent) at the completion of TPE Probe 2 will advance to Probe 3 of TPE after at least 45 days from completing the 1:1 post-probe education call date.</p>\n",
  "did": "00u8rclmm5",
  "title": "Pre-Payment Review Results for Remicade® (Infliximab) for October to December 2024",
  "displayTitle": "",
  "doctype": "article",
  "sortdate": "02/10/2025",
  "desc": "CMS implemented the Targeted Probe",
  "autourl": "",
  "truelastupdated": "02/20/2025 2:00:13 PM",
  "syncdom": "02/21/2025 11:50:10 AM",
  "publishdate": "02/20/2025",
  "template": "",
  "addSearchID": "t56j020lskz2isnrx1fcvy18ct8kpgba",
  "bc": [
    {
      "cat": "JMB~Medical Review~Targeted Probe and Educate",
      "doctype": "",
      "title": "Pre-Payment Review Results for Remicade® (Infliximab) for October to December 2024",
      "displaytitle": "",
      "lob": "jmb",
      "next": [
        {
          "title": "Topics",
          "url": "/jmb/admin/topics"
        },
        {
          "title": "Medical Review",
          "catlevel": "JMB~Medical Review",
          "url": "74H7NPMLXE"
        },
        {
          "title": "Targeted Probe and Educate",
          "catlevel": "JMB~Medical Review~Targeted Probe and Educate",
          "url": "ATZP575724"
        }
      ]
    }
  ],
  "rootCat": "Medical Review",
  "cat": "Medical Review~Targeted Probe and Educate",
  "cats": [
    "JMB~Medical Review~Targeted Probe and Educate"
  ],
  "cuwidget": [
    {
      "sitename": "JMB",
      "cat": "Medical Review",
      "realcat": "Medical Review",
      "did": "AB9OQXP6DN",
      "realtitle": "Contact JMB Medical Review",
      "key": {
        "lob": "JMB",
        "cat": "Medical Review"
      },
      "lob": "JMB"
    }
  ],
  "superAdState": false,
  "keywords": "TPE, Remicade, Infliximab",
  "news": "",
  "newsFlag": "",
  "updatedFlag": "",
  "superIntroState": false,
  "superTopicStartText": "",
  "lob": "jmb",
  "csortdate": "20250210",
  "cpublishdate": "20250220",
  "end": true
}